RORα and RORγ expression inversely correlates with human melanoma progression
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
// Anna A. Brożyna 1, 2 , Wojciech Jóźwicki 1, 2 , Cezary Skobowiat 3 , Anton Jetten 4 , Andrzej T. Slominski 5,6, 7 1 Department of Tumor Pathology and Pathomorphology, Oncology Centre - Prof. Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland 2 Department of Tumor Pathology and Pathomorphology, Faculty of Health Sciences, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland 3 Department of Pharmacodynamics and Molecular Pharmacology, Faculty of Pharmacy, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland 4 Cell Biology Section, Immunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA 5 Department of Dermatology, Cancer Chemoprevention Program, University of Alabama at Birmingham, AL, USA 6 Comprehensive Cancer Center, Cancer Chemoprevention Program, University of Alabama at Birmingham, AL, USA 7 Pathology and Laboratory Medicine Service, VA Medical Center, Birmingham, AL, USA Correspondence to: Anna A. Brożyna, email: anna.brozyna@cm.umk.pl Andrzej T. Slominski, email: aslominski@uabmc.edu Keywords: melanoma, RORα, RORγ, melanocytic nevi, vitamin D Received: February 19, 2016 Accepted: July 18, 2016 Published: August 11, 2016 ABSTRACT The retinoic acid-related orphan receptors (RORs) regulate several physiological and pathological processes, including immune functions, development and cancer. To study the potential role of RORs in melanoma progression, we analysed RORα and RORγ expression in nevi and primary melanomas and non-lesional skin and metastases in relation to melanoma clinico-pathomorphological features. The expression of RORα and RORγ was lower in melanomas than in nevi and decreased during melanoma progression, with lowest levels found in primary melanomas at stages III and IV and in melanoma metastases. Their expression correlated with pathomorphological pTNM parameters being low in aggressive tumors and being high in tumors showing histological markers of good prognosis. Higher nuclear levels of RORα and RORγ and of cytoplasmic RORγ correlated with significantly longer overall and disease free survival time. Highly pigmented melanomas showed significantly lower level of nuclear RORs. This study shows that human melanoma development and aggressiveness is associated with decreased expression of RORα and RORγ, suggesting that RORs could be important in melanoma progression and host responses against the tumor. Furthermore, it suggests that RORα and RORγ might constitute a novel druggable target in anti-melanoma management using tumor suppressor gene therapy restoring their normal functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Melanin pigmentation in mammalian skin and its hormonal regulation
Slominski, A., Tobin, D. J., Shibahara, S., & Wortsman, J. (2004) · Physiological Reviews · doi:10.1152/physrev.00044.2003 · Cited by 2,015 · cited 1×
“These results are also in accordance with a hypothesis that active melanogenesis can promotes melanoma progression [56, 57, 52, 58], and with previous research showing that melanogenesis can increase immune-, chemoand radioresistance of melanoma cells [59–64], and affects survival of melanoma patients after radiothera…”
ResultSelf-citationSuppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand
Solt, L. A., Kumar, N., Nuhant, P., Wang, Y., Lauer, J. L., Liu, J., Istrate, M. A., Kamenecka, T. M., Roush, W. R., Vidović, D., et al. (2011) · Nature · doi:10.1038/nature10075 · Cited by 508
Slominski, A. T., Kim, T., Shehabi, H. Z., Semak, I., Tang, E. K. Y., Nguyen, M. N., Benson, H. A. E., Korik, E., Janjetovic, Z., Chen, J., et al. (2012) · The FASEB Journal · doi:10.1096/fj.12-208975 · Cited by 266 · cited 1×
“These novel vitamin D3 hydroxyderivatives are produced ex-vivo by adrenal and placenta fragments as well as epidermal keratinocytes [15], and are detectable in human epidermis and serum [16].”
BackgroundSelf-citationThe ROR nuclear orphan receptor subfamily: Critical regulators of multiple biological processes
Jetten, A. M., Kurebayashi, S., & Ueda, E. (2001) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(01)69048-2 · Cited by 232
Self-citationMelanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma
Brożyna, A. A., Jóźwicki, W., Carlson, J. A., & Slominski, A. T. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.02.022 · Cited by 175 · cited 2×
“Proliferative activity, melanin content evaluation and TILs were performed as previously described [53, 9, 54, 10, 78, 79].”
MethodResultSelf-citationExpression of vitamin D receptor decreases during progression of pigmented skin lesions
Brożyna, A. A., Jozwicki, W., Janjetovic, Z., & Slominski, A. T. (2011) · Human Pathology · doi:10.1016/j.humpath.2010.09.014 · Cited by 120 · cited 7×
“This is consistent with our previous observation showing the reduction of OS and DFS of patients with a pigmented melanomas at stage 3 and 4 [53], and on expression of several vitamin D related pathways such as VDR, CYP24A1 and CYP27B1 [9, 54, 10] and HIF-1α [55].”
BackgroundMethodResultInfluentialSelf-citationSkobowiat, C., Sayre, R. M., Dowdy, J. C., & Slominski, A. T. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12096 · Cited by 115 · cited 1×
“We have followed protocols described previously in [81, 14].”
MethodSelf-citationJanjetovic, Z., Brozyna, A. A., Tuckey, R. C., Kim, T.-K., Nguyen, M. N., Jozwicki, W., Pfeffer, S. R., Pfeffer, L. M., & Slominski, A. T. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.458 · Cited by 91 · cited 1×
“Proliferative activity, melanin content evaluation and TILs were performed as previously described [53, 9, 54, 10, 78, 79].”
MethodSelf-citation
Cited by
Exploring vitamin D metabolism and function in cancer
Jeon, S.-M., & Shin, E.-A. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0038-9 · Cited by 550
Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship
Slominski, R. M., Sarna, T., Płonka, P. M., Raman, C., Brożyna, A. A., & Slominski, A. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.842496 · Cited by 286
Self-citationSlominski, A. T., Brożyna, A. A., Zmijewski, M. A., Jóźwicki, W., Jetten, A. M., Mason, R. S., Tuckey, R. C., & Elmets, C. A. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.3 · Cited by 136
Self-citationSlominski, A. T., Kim, T.-K., Hobrath, J. V., Janjetovic, Z., Oak, A. S. W., Postlethwaite, A., Lin, Z., Li, W., Takeda, Y., Jetten, A. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10202-7 · Cited by 82
Self-citationNoncalcemic 20-hydroxyvitamin D3 inhibits human melanoma growth in in vitro and in vivo models
Skobowiat, C., Oak, A. S. W., Kim, T.-K., Yang, C. H., Pfeffer, L. M., Tuckey, R. C., & Slominski, A. T. (2017) · Oncotarget · doi:10.18632/oncotarget.14193 · Cited by 44
Self-citation
Metadata
- Authors
- Brożyna, A. A., Jóźwicki, W., Skobowiat, C., Jetten, A., & Slominski, A. T.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-08-11
- Volume
- 7
- Issue
- 39
- Pages
- 63261-63282
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2516978391
- Cited by
- 70
- References
- 9
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.